{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:51:45Z","timestamp":1791154305472,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41440-026-02756-9","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:26:18Z","timestamp":1786584378000},"page":"2904-2907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Losartan, uric acid, and cardiometabolic disease: beyond blood pressure control"],"prefix":"10.1038","volume":"49","author":[{"given":"Masanari","family":"Kuwabara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsutaro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Ae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2756_CR1","doi-asserted-by":"publisher","unstructured":"Xu X, Naeem A, Emmett A, Siedlinski M, Chinoy H, Guzik TJ, et al. Urate-lowering effects of losartan: a meta-analysis and target trial emulation. Hypertens Res. 2026. https:\/\/doi.org\/10.1038\/s41440-026-02719-0.","DOI":"10.1038\/s41440-026-02719-0"},{"key":"2756_CR2","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397:1843\u201355.","journal-title":"Lancet"},{"key":"2756_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-018-1612-1","volume":"20","author":"PL Evans","year":"2018","unstructured":"Evans PL, Prior JA, Belcher J, Mallen CD, Hay CA, Roddy E. Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. Arthritis Res Ther. 2018;20:136.","journal-title":"Arthritis Res Ther"},{"key":"2756_CR4","doi-asserted-by":"crossref","unstructured":"Ohya Y, Arakawa K, Arata N, Arima S, Arima H, Asayama K, et al. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Hypertens Res. 2026;49:9\u2013235.","DOI":"10.1038\/s41440-025-02462-y"},{"key":"2756_CR5","doi-asserted-by":"publisher","first-page":"d8190","DOI":"10.1136\/bmj.d8190","volume":"344","author":"HK Choi","year":"2012","unstructured":"Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190.","journal-title":"BMJ"},{"key":"2756_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between Gout flare and subsequent cardiovascular events among patients with Gout. JAMA. 2022;328:440\u201350.","journal-title":"JAMA"},{"key":"2756_CR7","doi-asserted-by":"crossref","unstructured":"Cipolletta E, Sandstr\u00f6m TZ, Nakafero G, Rozza D, Drivelegka P, Moroncini G, et al. Association between tachyarrhythmia and gout flare in people with gout in England and Sweden: nested case\u2013control studies and self-controlled case-series analyses. Lancet Prim Care. 2026;2:100170.","DOI":"10.1016\/j.lanprc.2026.100170"},{"key":"2756_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/jamainternmed.2025.7453","volume":"186","author":"E Cipolletta","year":"2026","unstructured":"Cipolletta E, Zverkova Sandstrom T, Rozza D, Leyrat C, Nakafero G, Drivelegka P, et al. Treat-to-target urate-lowering treatment and cardiovascular outcomes in patients with Gout. JAMA Intern Med. 2026;186:332\u201342.","journal-title":"JAMA Intern Med"},{"key":"2756_CR9","doi-asserted-by":"publisher","unstructured":"Kuwabara M, Cicero AF, Akashi N, Ogino K, Ae R, Kohro T, et al. Uric acid and heart failure. J Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jjcc.2026.07.009.","DOI":"10.1016\/j.jjcc.2026.07.009"},{"key":"2756_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.1056","volume":"20","author":"UM Mogensen","year":"2018","unstructured":"Mogensen UM, Kober L, Jhund PS, Desai AS, Senni M, Kristensen SL, et al. Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018;20:514\u201322.","journal-title":"Eur J Heart Fail"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02756-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02756-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02756-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:03:04Z","timestamp":1791151384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02756-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2756"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02756-9","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MK has received research grants from JSPS KAKENHI (20K17168, 23K07493, and 26K11018) and from the Japanese Society of Gout and Uric & Nucleic Acid. The other authors declare that they have no potential conflicts of interest relevant to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}